CIPLA LIMITED
Cipla Limited, founded in 1935, is a global pharmaceutical leader headquartered in Mumbai, India. Known for its affordable and innovative medicines, Cipla operates in over 100 countries with a strong presence in respiratory, oncology, HIV/AIDS, and chronic care treatments. The company is committed to improving healthcare access and sustainability, making life-saving therapies available worldwide.
Product Mix
- India – Nicotex, Cofsils, Cipladine, ORS, Omnigel
- South Africa – Cipla Actin, Broncol, Flomist, Asthavent, coryx.
Shareholding Pattern
-PUBLIC GROUP
-PROMOTER GROUP
Financial Summary
| Particulars | March 2022 | March 2023 | March 2024 |
| Sales | 21,763 | 22,753 | 25,774 |
| Sales Growth % | 13.59% | 4.55% | 13.28% |
| Expenses | 17,211 | 17,726 | 19,483 |
| Operating Profit | 4,553 | 5,027 | 6,291 |
| OPM % | 21% | 22% | 24% |
| Net Profit | 2,547 | 2,833 | 4,154 |
| EPS in Rs | 31.19 | 34.71 | 51.05 |
Synopsis of Financials
- Reported quarterly revenue of ₹7,073 crores, reflecting an 8% year-on-year growth.
- EBITDA margin stood at 28%, an increase of 184 basis points YoY and 138 basis points QoQ.
- Profit after tax for the quarter was ₹1,571 crores, approximately 22% of sales, with an effective tax rate of 25.5%.
- Free cash flow generation and operating efficiencies have resulted in a healthy net cash position of ₹8,947 crores.
Final Outlook
CIPLA’s profit for the financial year 2023-24 showed a remarkable increase of approximately 62.22% compared to the previous financial year (2022-23). “Better days ahead” for the pharmaceutical giant, expecting Cipla to benefit from a slew of U.S. launches lined up, adding that it also expects the company to witness a domestic recovery and healthy growth in South Asia, which would drive a 9.5% reported EPS CAGR for Cipla over FY24-27.
Revenue: ₹257 billion (+18% YoY).
Net Profit: ₹41 billion (+73.05% YoY).
EPS: ₹51.5 (up from ₹35.1 in FY 2022-23).
Cash Flow: Operating cash flow rose to ₹41,339 million.
Dividend: ₹13 per share declared.
Market Position: 3rd largest in the Indian prescription market, with strong US and India sales.
CIPLA-LIMITED-PDF-Report